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ABSTRACT 
Mixed lineage leukemia 5 (MLL5) transactivates the expression of E6 and E7 oncogenes in cervical cancer cells. 
In this study, we utilized CRISPR/Cas9 system with the aim to target HPV-E6 and MLL5 to enhance apoptosis 
efficiency in HPV-18 positive HeLa cells and to improve chemotherapeutic efficacy of Cisplatin as the most com-
mon anticancer drug, used for cervical cancer. sgRNAs against MLL5 and E6 were designed and cloned into 
PX458 plasmid vector. Real-time PCR was used to determine knockout expression of MLL5 and E6 follow-
ing, transfection with cloned plasmids. Cell viability and apoptosis were evaluated, using Dimethyl-thiazolyl di-
phenyl tetrazolium bromide (MTT) assay and Annexin V flow cytometry. Cellular p53 level was measured, using 
enzyme linked immune sorbent assay (ELISA). Real-time PCR indicated the downregulation of E6 and MLL5 in 
the transfected cells. A significant increase in the accumulation of P53 was observed due to targeting MLL5 and 
E6 genes. MTT and apoptosis assays showed a significant decrease in cell viability and enhanced apoptosis rate 
of transfected cells. Combination therapy showed that targeting E6 and MLL5 enhanced apoptotic effect of Cis-
platin in MLL5 knockout cells in a synergistic manner. The results suggest that CRISPR/Cas9 targeting of E6 and 
MLL5 genes can increase apoptotic effects of Cisplatin and can be considered as a potential combination therapy 
for the treatment of HPV-related cervical cancer.  
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INTRODUCTION 
According to global cancer statistics 
2018, cervical cancer (CC) is the fourth cause 
of malignancies among women, with approx-
imately 570,000 of new cases and 300,000 of 
deaths per year (Bray et al., 2018). Infection 
with type 16 and 18 of Human Papilloma-
viruses (HPVs) is highly associated with the 
development of CC (Woodman et al., 2007). 
HPV carcinogenesis is the direct consequence 
of the integration and expression of E6 and 
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E7 oncogenes in cervical cells (Mighty and 
Laimins, 2014) as well as disruption of E2 
that acts in favor of repressing the expression 
of the oncogenes (Howley, 1991). E6 and E7 
expression contribute to the development of 
pre-cancerous cervical lesions through dereg-
ulation of the expression of P53 and Rb tumor 
suppressor genes, respectively (Zhen and Li, 
2017). The expression of E6 and E7 in CC 
cells is regulated by the beta isoform of mixed 
lineage leukemia (β-MLL5) protein that me-
diates the transcription of E6 and E7 genes via 
forming a complex with the AP-1 transcrip-
tion factor in Long Coding Region of HPV 
(Yew et al., 2011). Cheng et al. showed that 
knock down of MLL5, using siRNA leads to 
upregulation of P53, p21, and hypophosphor-
ylated Rb in HeLa cells (Cheng et al., 2008). 
Furthermore, it was revealed that β-MLL5 
forms a strong physical complex with P53, in-
hibiting its ability to bind with chromatin and 
halts its downstream processes. Yew et al. ob-
served the concurrent downregulation of E6 
and E7 in HPV positive HeLa cells and sug-
gesting β-MLL5 as a potential target for treat-
ment of HPV related cervical cancers (Yew et 
al., 2011). In addition, Nin et al. reported that 
siRNA-mediated knockdown of β-MLL5 
leads to growth inhibition via the activation of 
apoptosis and senescence on tumor growth 
rate and improves radiosensitization of Cis-
platin in HeLa cervical cancer cells in vitro 
and in vivo (Nin et al., 2014). All in all, these 
studies suggest MLL5 as a potential target for 
treatment of HPV-related cervical cancers. 
The current available therapeutic ap-
proaches for the treatment of CC pa-
tients include radical surgery, radiotherapy, 
chemotherapy, and chemoradiotherapy 
(Cadron et al., 2007; Lorusso et al., 2014). 
However, their efficiency is usually limited 
by several complications such as loss of fer-
tility and drug resistance. Particularly, CC pa-
tients treated with Cisplatin have shown to de-
velop resistance against Cisplatin and other 
platinum-based drugs, such as Carboplatin 
(Gore et al., 1989). P53 is well known as the 
underlying mechanism of increased tolerance 
against Cisplatin. In fact, activated P53 is a 
critical element for the appropriate Cisplatin-
induced apoptosis (Zhu et al., 2016). Thereby, 
loss of P53 can impair apoptosis process 
which leads to tolerance of DNA damage, 
consequently promoting drug resistance. It 
was stated that by inducing wild-type P53, the 
tolerance will resolve and the apoptotic path-
ways of the cell will be restored (Siddik et al., 
1999).  
Clustered regularly interspaced short pal-
indromic repeats (CRISPR)-associated pro-
tein 9 (Cas9) is a novel genome editing 
method with potential therapeutic application 
in treatment of various disorders (Baliou et 
al., 2018). It consists of a nuclease moiety (i.e. 
the Cas9) guided by a short RNA sequence 
(sgRNA) to the target DNA that exerts a dou-
ble stranded break (DSB) at the intended site 
(Jo et al., 2015). CRISPR/Cas9 can be easily 
programed to disrupt virtually any DNA tar-
get by merely exploiting an appropriately de-
signed 20 bp sgRNA (Jinek et al., 2012). 
Once the DSB is induced, the molecular ma-
chinery inside the cell will start to repair the 
break by a strong but infidel mechanism 
called non‐homologous end joining (NHEJ) 
process, which ultimately ends in induction of 
random indel mutations in the DSB site 
(Bernheim et al., 2017). CRISPR/Cas9 has 
shown to be effective in knockout of HPV on-
cogenes with the aim to prevent the tumor 
growth, and improvement of Cisplatin thera-
peutic efficiency (Zhen et al., 2016; Hu et al., 
2014; Hsu et al., 2018). 
In this study, we aimed to disrupt β-MLL5 
and E6 genes and examine their effects on vi-
ability of HPV18-positive HeLa cells. To this 
end, we have reprogrammed CRISPR/ Cas9 
genome editing system with the purpose of 
targeting β-MLL5 and E6, and evaluating 
their effects by measuring the alterations in 
the P53 protein level, cell viability, cell apop-
tosis and therapeutic activity of cisplatin. 
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MATERIALS AND METHODS 
Cloning and construction of sgRNA expres-
sion PX458 plasmids 
A series of sgRNAs were designed and 
analyzed, using sgRNA design tool available 
at https://crispr.mit.edu/, and DeskGene tool 
available at https://www.deskgen.com. Two 
sgRNAs were selected based on their score 
(the higher efficiency, and the fewer off tar-
gets) and their percent peptide. The sgRNAs 
were synthesized as oligonucleotide DNA se-
quences and cloned into PX458 plasmid 
(Addgene, Plasmid #48138) to construct 
two active CRISPR vectors; One construct 
targeting MLL5 gene (MLL5-sgRNA: 
ATCCGTAGAAGCTAGCCCTG) and the 
other one targeting E6 gene (E6-sgRNA: 
AGCTTGTAGGGTCGCCGTGT) (Figure 
1). Cloning was performed according to a pro-
tocol described by Ran et al. (2013). 
 
Cell culture 
HeLa and Hek-293 cell lines were pur-
chased by Pasteur Institute, Tehran, Iran. 
HeLa is an HPV18-positive cell line that con-
sistently expresses E6 and E7 oncogenes as 
well as MLL5 while Hek-293 is HPV nega-
tive, but expresses MLL5. The HeLa and 
Hek-293 cells were kept and grown in 
high glucose Dulbecco's Modified Eagle's 
Medium (DMEM) supplemented with 10 % 
FBS and 1 % Penicillin/Streptomycin 
(Sigma-Aldrich, USA).  
 
Transfection 
HeLa and Hek-293 cells in passage three 
were seeded in six well culture plates. Once 
the cells reached confluency of 50 %, they 
were transfected with MLL5-sgRNA, E6-
sgRNA or mock PX458 plasmids, using 
Transfectimine transfection reagent (Dara 
Zistfan Eram; Shiraz, Iran) according to the 
manufacturer’s protocol. Briefly, one tube 
containing plasmid DNA (9 µg), 200 µL of 
DMEM, and 10 % FBS, and another tube con-
taining Transfectimine (15 µL), 200 µL of 
DMEM, and 10 % FBS were prepared. Tubes 
were kept at room temperature for five min. 
Afterwards, they were mixed and incubated at 
room temperature for 20 min. The mixture 
was poured on the surface of culture media, 
and the cells were incubated for 8 hours at 
37 °C in 5 % CO2. At the end of this period, 
the medium was removed and the cells were 
carefully washed with PBS, and then cultured 
in fresh warm complete medium. 
 
 
 
 
Figure 1: The location of the designed sgRNAs on the coding sequence of the target genes (MLL5 exon 
4, and HPV-18 E6). MLL5-sgRNA had the percent peptide of 21 and MIT score of 81, located on the 
plus strand while the E6-sgRNA was located on minus strand with percent peptide of 5.2 and MIT score 
of 96. 
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Real-Time PCR 
Real time PCR was our method of choice 
to evaluate the expression of MLL5 and E6 
genes in treated target cells. Seventy-two 
hours after transfection, HeLa cells were sub-
jected to total RNA extraction procedure, us-
ing TRYzol RNA Extraction Reagent (Dara 
Zistfan Eram; Shiraz, Iran). Complementary 
DNA (cDNA) was synthesized, using Prime-
Script 1st strand cDNA Synthesis Kit 
(Takara, Japan), according to the manufac-
turer’s instructions. qPCR was performed on 
ABI 7500 Real Time Analyzer (Applied Bio-
system, USA), using high-ROX RealQ Plus 
2x Master Mix Green (Ampliqon, Denmark) 
and specific primers for MLL5, E6, and Beta-
2-microglobulin (B2M) genes (Table 1). The 
experiments were performed independently 
in a quadruplicate manner. 
 
Measurement of P53  
The P53 content of HeLa cells was meas-
ured, using Human P53 ELISA Kit (Diaclone, 
France. Cat#: 850.630.048). Seventy-two 
hours’ post-transfection, the transfected cells 
were lysed and their protein concentration 
was quantified using Coomassie Brilliant 
Blue G-250 Dye (Thermo Scientific, USA). 
One hundred µl of each sample was used for 
P53 ELISA in a duplicate array. ELISA was 
performed according to the manufacturer's in-
structions. P53 concentrations were normal-
ized and reported as percentage of untreated 
control cells for each sample.  
 
MTT assay 
Seventy-two hours after transfection, the 
cells were treated with 28.83 µM (IC50) 
of Cisplatin for 24 hours. The treated and con-
trol cells (without Cisplatin) were exposed to 
10 µL of Dimethyl-thiazolyl diphenyl tetrazo-
lium bromide (MTT; Sigma Aldrich, USA) in 
concentration of 5 mg/ml and incubated for 
four hours in 37 °C. Afterwards, 100 μL of 
Dimethyl sulfoxide (DMSO; Sigma Aldrich, 
USA) was added to each well and the plates 
were left in dark for 10 min. Finally, the ab-
sorbance of each well was measured in 
570 nm wavelength, using an ELISA reader 
instrument.  
 
Flow cytometry analysis of apoptosis 
Apoptosis assay was conducted 72 hours 
after transfection, using PE AnnexinV Apop-
tosis Detection Kit and FACSCan flow cy-
tometry system  (BD bioscience, USA) ac-
cording to the instructions provided by the 
manufacturer. A total number of 10,000 
events were obtained for each sample within 
one hour. 
 
Statistical analysis 
All the data were analyzed using 
IBM SPSS® software version 21.0 (IBM, 
USA). One-way ANOVA followed by LSD 
post-hoc comparison test, Mann-Whitney U 
test, and Kruskal-Wallis test were used for an-
alyzing the parametric and non-parametric 
data, respectively. P value less than 0.05 was 
considered to be statistically significant. 
 
 
 
Table 1: Primers used for quantitative real time PCR 
Primer Name Primer Sequence Product Length 
E6-Forward CACGGAACTGAACACTTC 121 bp 
E6-Reverse GTCTCTATACACCACAAATAAATC  
MLL5-Forward GGGAAGTTTATGCTGAGAGA 154 bp 
MLL5-Reverse AAGACCGCCTGATGAATC  
B2M-Forward AGATGAGTATGCCTGCCGTG 105 bp 
B2M-Reverse GCGGCATCTTCAAACCTCCA  
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RESULTS 
Transfection 
HeLa and Hek-293 cells were transfected 
with the cloned PX458 plasmid that carries 
the gene encoding for green fluorescence pro-
tein (GFP). The efficiency of transfection was 
evaluated by counting GFP expressing cells. 
A high intense fluorescence was observed 24 
hours after the transfection, suggesting that 
the cells were successfully transfected (Figure 
2). Counting the number of GFP expressing 
cells in at least five filed of the cultured cells 
revealed that the transfection efficiency was 
approximately 70 % and 40 % for the Hek-
293 and HeLa cells, respectively.  
Expression of MLL5 and E6 in HeLa Cells 
were reduced following transfection with 
E6 and MLL5 targeting CRISPR/Cas9  
constructs  
Seventy-two hours after transfection, the 
expression of MLL5 and E6 genes were eval-
uated, using real time PCR. The results 
showed a substantial reduction in the level of 
MLL5 mRNAs in the CRISPR/Cas9 trans-
fected cells compared to untreated control 
cells. Similarly, a significant reduction 
(p<0.05) in the level of E6 mRNA expression 
was observed in the cells transfected with E6 
sgRNA compared to untreated control cells 
(Figure 3). 
  
Figure 2: GFP expression was visualized directly by fluorescence microscopy to evaluate the transfec-
tion efficiency. A and B represent the Hek-293 cells transfected with PX458 plasmids containing MLL5 
and E6 sgRNAs. C and D represent HeLa cells transfected with PX458 plasmids containing MLL5 and 
E6 sgRNAs, respectively (Scale bars=20µM).  
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Figure 3: The expression of MLL5 and E6 was reduced 72 hours after HeLa cells were transfected with 
MLL5- and E6-targeting CRISPR/Cas9 system (MLL5-sgRNA and E6-sgRNA). Represented data are 
mean ± SD from four independent experiments. Data were analyzed using Mann-Whitney U test and 
p<0.05 was considered as significant difference between the groups. 
 
 
 
Elevation of P53 in HeLa cells following 
transfection with E6 and MLL5 targeting 
CRISPR/Cas9 constructs  
Due to the well-known effect of MLL5 on 
E6 expression and also the role of E6 on deg-
radation of P53, we evaluated the effects of 
MLL5 knockdown on intracellular accumula-
tion of P53, using ELISA method. The results 
of ELISA are summarized in Figure 4. An in-
crease in P53 protein level was observed fol-
lowing targeting of E6 genes (p=0.05). Simi-
larly, the intracellular accumulation of P53 
(p=0.006) was increased following targeting 
the MLL5 gene. No significant difference was 
observed in P53 levels between the MLL5 
and E6 group (p=0.433).  
The effect of E6 and MLL5 knockout on 
the viability of HeLa and Hek-293 cells 
To examine whether the knockout of E6 
and MLL5 would affect the cell viability, 
MTT assay was carried out four days after 
transfection. A statistically significant reduc-
tion in cell viability was observed in the HeLa 
cells following disruption of MLL5 and E6 in 
comparison with the untreated control group 
while in Hek-293 cells transfection with both 
MLL5 and E6 sgRNA had no significant ef-
fect on cell viability (Figure 5).  
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Figure 4: The effects of targeting MLL5 and E6 genes on intracellular accumulation of P53 in HeLa 
cells. P53 protein was measured using ELISA method and the data was expressed as percentage of 
the control group. The presented data are mean ± SD. Kruskal-Wallis method was used to analyze the 
data. P<0.05 was considered as significant difference between groups. 
 
 
 
 
Figure 5: Evaluating viability of HeLa (A) and Hek-293 (B) cells using MTT assay after CRISPR/Cas9-
targeting of MLL5 and E6. The presented data are mean± SD of at least four independent experiments. 
Data were analyzed, using one-way ANOVA followed by LSD post-hoc comparison test. P<0.05 was 
considered as significant difference between groups. 
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The effect of E6 and MLL5 targeting 
CRISPR/Cas9 constructs  on the efficiency 
of Cisplatin on HeLa Cells  
To examine whether the knockout of E6 
or MLL5 would increase the Cisplatin effi-
ciency, MTT assay was carried out on day 
five by treating cells with equal amounts of 
plasmids for each group, in combination with 
Cisplatin at its IC50 (28.83 µM). Results of the 
MTT assay exhibited strong synergisms be-
tween CRISP/Cas9 targeting of E6 or MLL5 
as well as anti-proliferative efficiency of Cis-
platin (Figure 6). 
 
Annexin V based apoptosis detection 
The apoptotic status of transfected cells 
was quantified, using Annexin V/7ADD flow 
cytometry method. Results indicated signifi-
cant apoptotic activities of E6 and MLL5 tar-
geting CRISPR/Cas9 constructs in HeLa cells 
(Figure 7) but not in Hek-293 cells (Figure 8). 
Moreover, treatment of HeLa cells with mock 
plasmid lead to no statistically significant 
apoptotic effects. In addition, flow cytometry 
results indicated a significant increase in 
apoptosis of HeLa cells treated with MLL5-
sgRNA or E6-sgRNA combined with Cispla-
tin in comparison with the cells treated with 
Cisplatin alone; further suggesting the syner-
gistic effect of CRISPR/Cas9-targeting of  
MLL5 and E6 on chemotherapeutic effi-
ciency of Cisplatin (Figure 9). Additionally, 
no significant difference was observed be-
tween MLL5-sgRNA+Cisplatin and E6-
sgRNA+Cisplatin groups. 
 
 
 
 
Figure 6: Evaluating viability of HeLa cells using MTT assay after CRISPR/Cas9-targeting of MLL5 and 
E6 with and without Cisplatin. The  represent data are mean ± SD of at least five independent experi-
ments. Data were analyzed, using one-way ANOVA followed by LSD post-hoc test. P<0.05 was consid-
ered as significant difference between groups. 
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Figure 7: The effect of MLL5-sgRNA and E6-sgRNA on the apoptosis of HeLa cells. Seventy-two hours 
after transfection with MLL5-sgRNA, E6-sgRNA, or mock plasmids the total number of apoptotic cells 
was quantified, using Annexin V/7AAD flow cytometry method. Data is expressed as percentage of 
apoptotic cells in 10000 events per sample. A: Untreated control cells, B: Cells transfected with PX458 
Mock plasmid, C: Cells transfected with plasmids harboring MLL5-sgRNA, D: Cells transfected with 
plasmids harboring E6-sgRNA. In each plot, Q1, Q2, Q3, and Q4 are necrotic (Annexin V-/7AAD+), late 
apoptotic (Annexin V+/7AAD+), early apoptotic (Annexin V+ and 7-AAD-), and viable (Annexin V- and 
7-AAD-) cells, respectively. On the graph, presented data are mean ± SD of total apoptotic cells. Data 
were analyzed using one-way ANOVA followed by LSD post-hoc test for multiple comparison. P < 0.05 
was considered as statistical difference. 
 
Figure 8: The effect of MLL5-sgRNA and E6-sgRNA on the apoptosis of Hek-293 cells. Seventy-two 
hours after ith MLtransfection w L5-sgRNA, E6-sgRNA, or mock (empty PX458) plasmids the total num-
ber of apoptotic cells was quantified, using Annexin V/7AAD flow cytometry method. Data is expressed 
as percentage of apoptotic cells in 10000 events per sample. A: Untreated control cells, B: Cells trans-
fected with PX458 mock plasmid, C: Cells transfected with plasmids harboring ML L5-sgRNA, D: Cells 
transfected with plasmids harboring E6-sgRNA. In each plot, Q1, Q2, Q3, and Q4 are necrotic (Annexin 
V-/7AAD+), late apoptotic (Annexin V+/7AAD+), early apoptotic (Annexin V+ and 7-AAD-), and viable 
(Annexin V- and 7-AAD-) cells, respectively. On the graph, presented data are mean ± SD of total apop-
totic cells. Data were analyzed using one-way ANOVA followed by LSD post-hoc test for multiple com-
parison. No significant differences were observed between various groups at P < 0.05. 
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Figure 9: The effect of MLL5-sgRNA and E6-sgRNA alone or in combination with Cisplatin on the apop-
tosis of HeLa cells. Two days after transfection with MLL5-sgRNA, E6-sgRNA, or mock plasmids, the 
cells were treated with Cisplatin at its IC50. Twenty-four hours later the total number of apoptotic cells 
was quantified, using Annexin V/7AAD flow cytometry method. Data is expressed as percentage of 
apoptotic cells in 10,000 events per sample. A: Untreated control cells, B: Cells transfected with PX458 
Mock plasmid, C: Cells transfected with plasmids harboring MLL5-sgRNA, D: Cells transfected with 
plasmids harboring E6-sgRNA. In each plot, Q1, Q2, Q3, and Q4 are necrotic (Annexin V-/7AAD+), late 
apoptotic (Annexin V+/ 7AAD+), early apoptotic (Annexin V+ and 7-AAD-), and viable (Annexin V- and 
7-AAD-) cells, respectively. On the graph, presented data are mean ± SD of total apoptotic cells. Data 
were analyzed using one-way ANOVA followed by LSD post-hoc test for multiple comparison. P < 0.05 
was considered as statistical difference. 
 
 
DISCUSSION 
The recent progresses in the CRISPR/ 
Cas9 gene editing technology have led to new 
opportunities in cancer gene therapy (Baliou 
et al., 2018; Lino et al., 2018). Cancers are 
heterogeneous complex molecular disorders, 
resulting by abnormalities in a numerous of 
genes and signaling pathways. Thus, selecting 
of appropriate target gene is the most critical 
step which determines the success of gene 
therapeutic methodologies including 
CRISPR/Cas9. The rationale for choosing 
MLL5 gene in the current study was its regu-
latory role in proliferation of HeLa cells by 
binding to P53 and controlling its bioavaila-
bility. Moreover, human MLL5 gene is ex-
pressed as full-length MLL5, MLL5α, and 
NKp44L isoforms in many human tissues 
while it is exclusively expressed as MLL5β in 
HPV16/18-cervical cancer cells, where it par-
ticipates in activation of E6/E7 transcription. 
These characteristics make MLL5 gene an 
ideal target for the gene therapy of HPV16/18 
positive CC. In this regard, some previous 
studies have evaluated the effects of slicing of 
MLL5β transcription, using siRNA or inhibi-
tion of post translational acylation of MLL5β 
on viability and apoptosis of CC cells (Yew et 
al., 2011; Cheng et al., 2008, 2011; Nin et al., 
2014). To the best of our knowledge, the pre-
sent study is the first to utilize CRISPR/Cas9 
technology for targeting MLL5 in combina-
tion with Cisplatin, and to evaluate the effects 
of this knockout on the viability and apoptosis 
of HeLa CC cells. Our findings revealed a sig-
nificant increase in P53 level, reduction in cell 
viability, and increase in apoptosis of HeLa 
cells following targeting of both MLL5 and 
E6 genes. Cytotoxicity of Cisplatin was also 
increased following knockout of MLL5 and 
E6 genes. These findings suggest that 
CRISPR/Cas9-mediated knockout of MLL5 
and E6 in combination with chemotherapy, 
might have potential therapeutic benefits in 
the treatment of HPV16/18 positive cervical 
cancer. 
The first and critical step in the CRISPR/ 
Cas9 gene editing technology, which deter-
mines its specificity, is the design of the 
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CRISPR sgRNA with the highest activity 
score and the least off-targets. In the present 
study, we designed and synthesized a sgRNA 
that targeted exon 4 within the MLL5 gene. 
This sgRNA can disrupt β-isoform of MLL5 
which is specifically expressed in HeLa cells. 
The results of real time PCR revealed a reduc-
tion in MLL5 expression in the HeLa cells, 
following transfection with the plasmids har-
boring MLL5-sgRNA. Similar results were 
obtained for E6 gene in HeLa cells treated 
with E6-sgRNA plasmid. These findings in-
dicated that knocking out of MLL5 and E6 
had efficiently occurred within the targeted 
regions. 
Our data clearly exhibits a significant de-
crease in viability of HeLa cells but not Hek-
293 cells, following knock out of MLL5 and 
E6, suggesting the specificity of this method 
in reducing viability of HPV-positive cells 
which is consistent with the results reported 
by Nin et al. (2014) and Kennedy et al. 
(2014). In line with the findings of previous 
studies (Yew et al., 2011; Nin et al., 2014; Hu 
et al., 2014), results of flow cytometric apop-
tosis assay revealed a significant increase in 
the rate of apoptosis in HPV-18 positive cells 
following knockout of both E6 and MLL5 
genes, a phenomenon not observed in Hek-
293 cells, further suggesting the specificity 
and also the role of apoptosis in the anti-via-
bility effects of our approach. Finally, the re-
sults of cell viability and apoptosis assays 
clearly showed that knockout of both MLL5 
and E6 had synergistic effects on the anti-can-
cer efficiency of Cisplatin, which is in corre-
lation with previous findings by others; In 
vitro and in vivo studies conducted by Zhen et 
al., which showed that HPV16 E6/E7-
CRISPR/Cas9 could effectively and specifi-
cally increase the cell-sensitivity to Cisplatin 
(Zhen et al., 2016). Furthermore, Nin et al. 
(2014) revealed anti-proliferative and 
proapoptotic effects of siRNA-mediated si-
lencing of MLL5β in HeLa cells both in vitro 
and xenograft tumor models. They also 
demonstrated that cytotoxic effect of gamma 
irradiation on viability of HeLa cells to in-
crease, following MLL5β silencing while its 
overexpression reduced the effect of Cisplatin 
on radio-sensation of these cells (Nin et al., 
2014). 
Considering the well-known effect of E6 
on disruption of P53, and also the potential in-
direct effect of MLL5 on the bioavailability of 
P53, which is mediated through increasing 
E6, we evaluated the effects of E6 and MLL5 
knockout on the cellular accumulation of P53 
in transfected HeLa cells. The results of P53 
ELISA assay revealed a significant increase 
in cellular P53 accumulation in transfected 
cells compared to non-transfected control 
group. A finding that provided a plausible ex-
planation for the reduced cell proliferation 
and increased apoptosis, and the elevation in 
sensitivity to Cisplatin as observed in E6 and 
MLL5-knockout cells. This finding is in 
agreement with the results of others who re-
ported that cellular level of P53 is elevated 
following both MLL5 and E6 silencing (Yew 
et al., 2011; Cheng et al., 2008). 
In conclusion, our results further indicated 
the role of MLL5 in carcinogenesis of HPV 
positive cervical cancer cells. Moreover, we 
found that CRISPR/Cas9 mediated disruption 
of MLL5 has a higher negative impact on the 
viability of cancer cells in comparison with 
that of E6. This might be due to the simulta-
neous contribution of MLL5 to the expression 
of both E6 and E7; in addition to its role in 
degradation of P53. For the first time, we re-
vealed that MLL5 knockout has a significant 
impact on the chemotherapeutic efficiency of 
Cisplatin in HPV-18 positive cells. All in all, 
these findings suggest MLL5 as a possible 
novel target for the treatment of CC. How-
ever, this would not result in a desirable ac-
tion unless an efficient and tissue specific 
CRISPR expression system is facilitated; a 
goal being pursued by several research teams 
with promising results (Eoh and Gu, 2019; 
Chira et al., 2018; Zhu et al., 2018). 
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